Physician profile
Richard E Nickowitz
NPI 1083686893
$12,762.86
in general payments reported to CMS, 2019-2025
28 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,982 · 2020: $725 · 2021: $924 · 2022: $2,081 · 2023: $593 · 2024: $844 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011 · Education: $39.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,011.03 |
| Education | $39.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,160.01 | 2019-2025 | |
| Abbvie INC. | $3,545.98 | 2019-2025 | |
| Janssen Biotech, INC. | $1,303.89 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $492.16 | 2019-2025 | Entyvio |
| Qol Medical, LLC | $416.23 | 2020-2022 | |
| Boston Scientific Corporation | $342.47 | 2019-2025 | Spyglass |
| Janssen Scientific Affairs, LLC | $242.54 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.86 | 2019-2020 | |
| Olympus America INC. | $150.00 | 2022 | |
| Ardelyx, INC. | $145.93 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $124.99 | 2025 | Zenpep |
| Medtronic, INC. | $87.16 | 2021-2024 | Gi Genius |
| Redhill Biopharma INC. | $71.39 | 2021-2022 | |
| Gilead Sciences, INC. | $61.98 | 2019 | |
| Shionogi INC | $51.40 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $51.17 | 2023-2025 | Rebyota |
| Lilly USA, LLC | $47.49 | 2023-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $47.19 | 2019-2020 | |
| Celltrion USA INC. | $39.68 | 2024 | Zymfentra |
| Mauna Kea Technologies, INC. | $33.51 | 2019 | |
| Mallinckrodt Hospital Products INC. | $30.56 | 2024 | Terlivaz |
| Ambu INC. | $30.54 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.76 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $21.85 | 2024 | Voquezna |
| Allergan, INC. | $19.55 | 2019 | |
| Celgene Corporation | $18.23 | 2022 | |
| Capsovision, INC. | $16.98 | 2023 | Capsocam Plus |
| Intercept Pharmaceuticals, INC. | $15.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Nickowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.